Results 221 to 230 of about 201,283 (312)
Ira L. Leeds, MD, MBA, ScM, FACS, FASCRS. [PDF]
Steele SR.
europepmc +1 more source
ABSTRACT Background Advanced heart failure (HF) remains a clinical challenge, and mitral transcatheter edge‐to‐edge repair (M‐TEER) has emerged as a potential bridging strategy. Aims To describe the clinical outcomes of M‐TEER in a single‐center cohort of patients with advanced HF and to identify anatomical and clinical features potentially associated ...
Pedro Castilhos de Freitas Crivelaro +8 more
wiley +1 more source
Semiembedded HDPE/VIS Composite Membranes with Tailored Wettability and Superior Mechanical Durability for Outdoor Protective Applications. [PDF]
Zhang H, Zhai Q, Zhen Q, Lv H, Ye K.
europepmc +1 more source
Making Two out of One: Kinesin Motors Driving Plant Cell Division
ABSTRACT The Kinesin superfamily of microtubule dependent motors is present in all eukaryotes. Not all of the subfamilies are represented in all kingdoms, and the ones that are do not always show conserved functions. Tight control of the cytoskeleton is essential for proper progression and completion of mitosis and cytokinesis, and key functions are ...
Choy Kriechbaum, Sabine Müller
wiley +1 more source
ABSTRACT Cells sense the stiffness of their extracellular matrix (ECM) and adapt their behavior accordingly. We investigated how ECM stiffness affects the spatial organization of talin1, a key mechanosensitive focal adhesion protein. Using polyacrylamide (PA) hydrogels with tunable stiffnesses (0.2–188 kPa), we analyzed cell morphology, migration ...
Joanna Hajduk +5 more
wiley +1 more source
Macroplastic accumulation across different surface covers, a case study of two South African rivers. [PDF]
Mutshekwa T +6 more
europepmc +1 more source
Optimal deep learning based vehicle detection and classification using chaotic equilibrium optimization algorithm in remote sensing imagery. [PDF]
Alotaibi Y +3 more
europepmc +1 more source
Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu +5 more
wiley +1 more source

